CYTRX CORPORATION (NASDAQ:CYTR) Files An 8-K Financial Statements and Exhibits
Item 9.01
| Exhibits |
(d) Exhibits
There is filed as part of this report the exhibit listed on the
accompanying Exhibit Index, which information is incorporated
herein by reference.
|
|
About CYTRX CORPORATION (NASDAQ:CYTR)
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi’s sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology. CYTRX CORPORATION (NASDAQ:CYTR) Recent Trading Information
CYTRX CORPORATION (NASDAQ:CYTR) closed its last trading session down -0.176 at 0.509 with 25,738,684 shares trading hands.